Nephrology

medical specialties

The week's innovation in nephrology, published every Sunday for the week before: new technology, AI tools, devices, FDA decisions on new technology and new ways of delivering care, every item linked to its sources.

FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant

A hollow-fiber dialyzer held upright in a clamp on a short pole, its clear housing showing fine fibers, with tubing arching from its top cap.

The Food and Drug Administration (FDA) on Nov. 13 approved Gazyva (obinutuzumab), the first drug specifically for primary membranous nephropathy, after 36% complete remission versus 6% with tacrolimus.

A randomized trial found dapagliflozin improved eGFR slope in heart transplant recipients, and pegcetacoplan kept proteinuria down through one year in C3 glomerulopathy.

Latest news

Tagged nephrology, from the daily briefing

  1. Prespecified FIND-CKD analysis examines finerenone in focal segmental glomerulosclerosis
  2. FDA approves obinutuzumab as the first drug for primary membranous nephropathy after 36% reached remission versus 6% on tacrolimus
  3. National Kidney Foundation workshop says measuring urine albumin is generally preferred over total urine protein

See all the latest news

Earlier weeks

The weekly podcast

Each Sunday's nephrology innovation roundup as a short audio briefing, read by AI voices. Play any episode here, or follow the show in any podcast app.

In any podcast app, add the feed: https://feeds.transistor.fm/physician-in-the-loop-nephrology